MAM
PHAT icon

Meeder Asset Management’s Phathom Pharmaceuticals PHAT Stock Holding History

Meeder Asset Management’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-177
Closed -$5K – 2357
2020
Q1 		$5K Buy
+177
New +$5.92K ﹤0.01% 1798

Other funds holding PHAT

FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Meeder Asset Management's PHAT Position: Q2 2020 in Review

Meeder Asset Management sold out of Phathom Pharmaceuticals (PHAT) in Q2 2020, closing a stake of 177 shares — an estimated $5K sold.

Meeder Asset Management first reported a position in PHAT in Q1 2020 and held it in 1 quarter. The position peaked at $5K in Q1 2020. 61 funds tracked by Wall St. Rank hold PHAT as of Q2 2020.

  • Meeder Asset Management reported no remaining Phathom Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Meeder Asset Management sold 177 Phathom Pharmaceuticals shares in Q2 2020, an estimated $5K.
  • Meeder Asset Management first reported a position in Phathom Pharmaceuticals in Q1 2020 and held it in 1 quarter.
  • Meeder Asset Management's Phathom Pharmaceuticals position peaked at $5K in Q1 2020.
  • 61 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2020.

Based on Meeder Asset Management's 13F filing for Q2 2020, filed 11 Aug 2020.